Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27565. [Epub ahead of print]

PMID:
30575996
2.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
3.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
4.

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.

5.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM.

Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14.

PMID:
23770260
6.

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM.

Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3.

PMID:
23281915
7.

Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.

Fernagut PO, Li Q, Dovero S, Chan P, Wu T, Ravenscroft P, Hill M, Chen Z, Bezard E.

PLoS One. 2010 Nov 22;5(11):e14053. doi: 10.1371/journal.pone.0014053.

8.

Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.

Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I.

Exp Neurol. 2009 Oct;219(2):574-82. doi: 10.1016/j.expneurol.2009.07.019. Epub 2009 Jul 25.

PMID:
19635479
9.

Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease.

Scheller D, Stichel-Gunkel C, Lübbert H, Porras G, Ravenscroft P, Hill M, Bezard E.

Neurosci Lett. 2008 Feb 13;432(1):30-4. Epub 2007 Dec 8.

PMID:
18162314
10.

Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.

Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E.

Exp Neurol. 2007 Feb;203(2):415-22. Epub 2006 Oct 12.

PMID:
17045989
11.

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.

Mov Disord. 2006 Dec;21(12):2090-5.

PMID:
16991143
12.

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.

van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM.

FASEB J. 2005 Jul;19(9):1140-2. Epub 2005 May 13.

PMID:
15894565
13.

Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.

Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H.

Clin Neuropharmacol. 2004 Jul-Aug;27(4):171-7.

PMID:
15319703
14.

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

Meissner W, Hill MP, Tison F, Gross CE, Bezard E.

Trends Pharmacol Sci. 2004 May;25(5):249-53. Review.

PMID:
15120490
15.

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.

J Pharmacol Exp Ther. 2004 Jul;310(1):386-94. Epub 2004 Mar 5.

PMID:
15004218
16.

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M.

J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. Epub 2004 Feb 20.

PMID:
14978195
17.

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.

Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.

Eur J Pharmacol. 2004 Feb 6;485(1-3):159-64.

PMID:
14757136
18.

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.

Mov Disord. 2003 Nov;18(11):1301-5.

PMID:
14639671
19.

Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease.

Hill MP, Hille CJ, Brotchie JM.

Drug News Perspect. 2000 Jun;13(5):261-8.

PMID:
12937640
20.

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM.

Mov Disord. 2003 Aug;18(8):872-83.

PMID:
12889076

Supplemental Content

Loading ...
Support Center